1. From the INSERM, U872 Physiopathology of Ocular Diseases/Therapeutic Innovations, Paris, France; 2Centre de Recherche des Cordeliers, Université Pierre et Marie Curie—Paris6, UMR S 872, Paris, France; 3Université Paris Descartes, UMR S 872, Paris, France;
2. RibOvax Biotechnologies S.A., Geneva, Switzerland; and